These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 2545333)

  • 41. Endothelial cell lysis induced by lymphokine-activated human peripheral blood mononuclear cells.
    Miltenburg AM; Meijer-Paape ME; Daha MR; Paul LC
    Eur J Immunol; 1987 Sep; 17(9):1383-6. PubMed ID: 3308489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.
    Ochoa AC; Gromo G; Alter BJ; Sondel PM; Bach FH
    J Immunol; 1987 Apr; 138(8):2728-33. PubMed ID: 2435804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Human LAK cell induction and its biological characteristics].
    Wu YY
    Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):254-7. PubMed ID: 2125554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
    Lanier LL; Benike CJ; Phillips JH; Engleman EG
    J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Experimental studies on induction of various lymphokine-activated killer cells using recombinant interleukin 2].
    Takao H; Saji S; Sugiyama Y; Tachibana S; Goshima H; Morita T; Sakata K
    Nihon Geka Gakkai Zasshi; 1988 May; 89(5):646-54. PubMed ID: 3261830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lysis of tumor cells by CD3+4-8-16+ T cell receptor alpha beta- clones, regulated via CD3 and CD16 activation sites, recombinant interleukin 2, and interferon beta 1.
    van de Griend RJ; Tax WJ; van Krimpen BA; Vreugdenhil RJ; Ronteltap CP; Bolhuis RL
    J Immunol; 1987 Mar; 138(5):1627-33. PubMed ID: 2949018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Natural cytotoxicity in the neonate: high levels of lymphokine activated killer (LAK) activity.
    Montagna D; Maccario R; Ugazio AG; Mingrat G; Burgio GR
    Clin Exp Immunol; 1988 Jan; 71(1):177-81. PubMed ID: 2964956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
    Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
    Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
    Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
    Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S; Suttmann H; Riemensberger J; Seitzer U; Arnold J; Durek C; Jocham D; Flad HD; Böhle A
    Clin Cancer Res; 2000 Sep; 6(9):3729-38. PubMed ID: 10999767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma.
    LeFever AV; Funahashi A
    Cancer Res; 1991 Oct; 51(20):5596-601. PubMed ID: 1655257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interferon-gamma protects human endothelial cells from lymphokine-activated killer cell-mediated lysis.
    Renkonen R; Ristimäki A; Häyry P
    Eur J Immunol; 1988 Nov; 18(11):1839-42. PubMed ID: 3144455
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human spleen and peripheral blood lymphocytes activated by interleukin-2 have similar phenotypic and functional characteristics.
    Voltarelli JC; Rayner AA; Garovoy MR; Stites DP
    J Biol Response Mod; 1990 Feb; 9(1):103-7. PubMed ID: 2319257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
    Yamaguchi Y; Hironaka K; Okawaki M; Okita R; Matsuura K; Ohshita A; Toge T
    Anticancer Res; 2005; 25(2A):827-32. PubMed ID: 15868915
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
    Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K
    No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.
    Shimizu K; Park K; Yamada M; Tarura K; Matsui Y; Hayakawa T
    J Clin Lab Immunol; 1990 May; 32(1):41-7. PubMed ID: 1967036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.